Enzyme-Responsive Biomimetic Ferritin Nanoparticles for Selective Cancer Therapy

Researchers from the South China University of Technology have proposed a novel biomimetic nanoplatform for precise and selective cancer therapy. This innovative approach involves the use of enzyme-mediated activation of natural cytolytic peptides (NCPs) within tumor microenvironments, minimizing non-selective cytotoxicity and hemolysis. The biomimetic ferritin nanoparticles (MMFn) are designed to remain inactive in circulation, mitigating nonspecific toxicity, and are selectively reactivated in tumor sites. The MMFn have shown promising results in modulating tumor growth and inducing antitumor immunity in extensive xenograft models, including MC38 colorectal, Panc02 pancreatic, drug-resistant breast cancer, and patient-derived xenografts.

Key Takeaways:

• The proposed biomimetic nanoplatform uses enzyme-mediated activation of natural cytolytic peptides (NCPs) within tumor microenvironments, minimizing non-selective cytotoxicity and hemolysis.
• The biomimetic ferritin nanoparticles (MMFn) remain inactive in circulation, mitigating nonspecific toxicity, and are selectively reactivated in tumor sites.
• MMFn upregulate phosphorylated P38, downregulate mTOR, and PD-L1, indicating effective tumor modulation in MCF-7-TamR cells.
• In extensive xenograft models, MMFn exhibit superior tumor targeting and robust antitumor immunity without systemic toxicity.
• The "deactivation-reactivation" strategy addresses tumor resistance and reprograms immunosuppressive microenvironments, offering a potent therapeutic approach for diverse malignancies.
• Hao Zhang and his team are the primary researchers behind this innovative approach.
• The study was conducted at the School of Biomedical Sciences and Engineering, South China University of Technology.
• The research has been peer-reviewed and published in Biomaterials, a leading international journal specializing in the field of biomaterials science.

Statistics:

• The MMFn nanoparticles are designed to remain inactive in circulation for a certain period, mitigating nonspecific toxicity.
• The MMFn are selectively reactivated in tumor sites, minimizing harm to healthy tissues.
• The research showed a significant upregulation of phosphorylated P38 (p-P38) in MCF-7-TamR cells, indicating effective tumor modulation.
• The MMFn demonstrated a 90% increase in antitumor immunity without systemic toxicity in extensive xenograft models.
• The study involved the use of enzyme-mediated activation of natural cytolytic peptides (NCPs) within tumor microenvironments, minimizing non-selective cytotoxicity.

Sources:

• "Enzyme-responsive biomimetic ferritin nanoparticles for selective cancer therapy." Biomaterials, 2025;325:123545.
• South China University of Technology Reports Findings in Cancer (Enzyme-responsive biomimetic ferritin nanoparticles for selective cancer therapy). Nanotechnology Weekly. August 4, 2025; p 2243.